Peptide mimetic design with the aid of computational chemistry

Reviews in Computational Chemistry

Volumn 9, Issue , 1996, Pages 1-79

  Damewood Jr , James R ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PEPTIDES;

ANGIOTENSIN II; ELASTASE; NEUROTENSIN; PEPTIDE MIMETIC; THERMOLYSIN;

COMPUTATIONAL CHEMISTRY;

EID: 0345664910     PISSN: 10693599     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Article

References (219)

1. D. J. Ward, in Peptide Pharmaceuticals, D. J. Ward, Ed., Elsevier, New York, 1991, pp. 1-17. Introduction to Peptide Pharmaceuticals.
2. V. J. Hruby, W. Kazmierski, A. M. Kawasaki, and T. O. Matsunaga, in Peptide Pharmaceuticals, D. J. Ward, Ed., Elsevier, New York, 1991, pp. 135-184. Synthetic Chemistry and the Design of Peptide-Based Drugs.
3. M. D. Taylor, Peptide-Based Drug Design: Controlling Transport and Metabolism, American Chemical Society, Washington, DC, 1995.
4. A. Giannis and T. Kolter, Angew. Chem. Int. Ed. Engl., 32, 1244 (1993). Peptidomimetics for Receptor Ligands - Discovery, Development and Medicinal Perspectives.
5. R. A. Wiley and D. H. Rich, Med. Res. Rev. 13, 327 (1993). Peptidomimetics Derived from Natural Products.
6. M. Kahn, Synlett, 11, 821 (1993). Peptide Secondary Structure Mimetics: Recent Advances and Future Challenges.
7. G. L. Olson, D. R. Bolin, M. P. Bonner, M. Bös, C. M. Cook, D. C. Fry, B. J. Graves, M. Hatada, D. E. Hill, M. Kahn, V. S. Madison, V. K. Rusiecki, R. Sarabu, J. Sepinwall, G. P. Vincent, and M. E. Voss, J. Med. Chem., 36, 3039 (1993). Concepts and Progress in the Development of Peptide Mimetics.
8. R. M. J. Liskamp, Recl. Trav. Chim. Pays-Bas, 113, 1 (1994). Conformationally Restricted Amino Acids and Dipeptides (Non)Peptidomimetics and Secondary Structure Mimetics.
9. A. E. P. Adang, P. H. H. Hermkens, J. T. M. Linders, H. C. J. Ottenheijm, and C. J. van Staveren, Recl. Trav. Chim. Pays-Bas, 113, 63 (1994). Case Histories of Peptidomimetics: Progress from Peptides to Drugs.
10. J. Gante, Angew. Chem. Int. Ed. Engl., 33, 1699 (1994). Peptidomimetics - Tailored Enzyme Inhibitors.
11. J. A. Sikorski, Ed., Bioorg. Med. Chem. Symposium in Print 2, 2, pp. 847 ff. (1994). Applications of Peptidomimetics in Drug Design.
12. M. Goodman and S. Ro, in Burger's Medicinal Chemistry and Drug Discovery, 5th ed., M. E. Wolff, Ed., Wiley, New York. 1995, Vol. 1, pp. 803-861. Peptidomimetics for Drug Design.
13. M. Kahn, Ed., Tetrahedron Symposiwn-in-Print 50, 49, pp. 3433 ff. (1993). Peptide Secondary Structure Mimetics.
14. V. N. Balaji and U. C. Singh, U.S. Patent 5,331,573 (1994). Method of Design of Compounds That Mimic Conformational Features of Selected Peptides.
15. I. D. Kuntz, E. C. Meng, and B. K. Shoichet, Acc. Chem. Res., 27, 117 (1994). Structure-Based Molecular Design.
16. S. H. Rotstein and M. A. Murcko, J. Med. Chem., 36, 1700 (1993). GroupBuild: A Fragment-Based Method for De Novo Drug Design.
17. See, for example, W. H. Parsons, A. A. Patchett, M. K. Holloway, G. M. Smith, J. L. Davison, V. J. Lotti, and R. S. L. Chang, J. Med. Chem., 32, 1681 (1989). Cholecystokinin Antagonists. Synthesis and Biological Evaluation of 3-Substituted Benzolactams. See also references therein.
18. See, for example, A. van der Bent, A. G. S. Blommaert, C. T. M. Melman, A. P. Ijzerman, I. van Wijngaarden, and W. Soudijn, J. Med. Chem., 35, 1042 (1992). Hybrid Cholecystokinin-A Antagonist Based on Molecular Modeling of Lorglumide and L-364,718.
19. D. F. Veber, in Peptides: Proceedings of the Twelfth American Peptide Symposium, J. A. Smith and J. E. Rivier, Eds., ESCOM, Leiden, 1992, pp. 3-14. Design and Discovery in the Development of Peptide Analogs.
20. See, for example, E. A. Dratz, J. E. Furstenau, C. G. Lambert, D. L. Thireault, H. Rarick, T. Schepers, S. Pakhlevaniants, and H. E. Hamm, Nature, 363, 276 (1993). NMR Structure of a Receptor-Bound G-Protein Peptide.
21. P. R. Bernstein, P. D. Edwards, and J. C. Williams, Progr. Med. Chem., 31, 59 (1994). Inhibitors of Human Leukocyte Elastase.
22. P. D. Edwards and P. R. Bernstein, Med. Res. Rev. 14, 127 (1994). Synthetic Inhibitors of Elastase.
23. D. J. Hlasta and E. D. Pagani, Annu. Rep. Med. Chem., 29, 195 (1994). Human Leukocyte Elastase Inhibitors.
24. F. J. Brown, D. W. Andisik, P. R. Bernstein, C. B. Bryant, C. Ceccarelli, J. R. Damewood, Jr., P. D. Edwards, R. A. Earley, S. Feeney, R. C. Green, B. Gomes, B. J. Kosmider, R. D. Krell, A. Shaw, G. B. Steelman, R. M. Thomas, E. P. Vacek, C. A. Veale, P. A. Tuthill, P. Warner, J. C. Williams, D. J. Wolanin, and S. A. Woolson, J. Med. Chem., 37, 1259 (1994). Design of Orally Active, Non-Peptidic Inhibitors of Human Leukocyte Elastase.
25. P. Warner, R. C. Green, B. Gomes, and A. M. Strimpler, J. Med. Chem., 37, 3090 (1994). Non-Peptidic Inhibitors of Human Leukocyte Elastase. 1. The Design and Synthesis of Pyridone-Containing Inhibitors.
26. J. R. Damewood, Jr., P. D. Edwards, S. Feeney, B. C. Gomes, G. B. Steelman, P. A. Tuthill, J. C. Williams, P. Warner, S. A. Woolson, D. J. Wolanin, and C. A. Veale, J. Med. Chem., 37, 3303 (1994). Nonpeptidic Inhibitors of Human Leukocyte Elastase. 2. Design, Synthesis, and In Vitro Activity of a Series of 3-Amino-6-Arylopyridin-2-one Trifluoromethyl Ketones.
27. P. R. Bernstein, D. Andisik, P. Bradley, C. B. Bryant, C. Ceccarelli, J. R. Damewood, Jr., R. Earley, S. Feeney, B. C. Gomes, B. J. Kosmider, G. B. Steelman, R. M. Thomas, E. P. Vacek, C. A. Veale, J. C. Williams, D. J. Wolanin, and S. A. Woolson, J. Med. Chem., 37, 3313 (1994). Nonpeptidic Inhibitors of Human Leukocyte Elastase. 3. Design, Synthesis, X-Ray Crystallographic Analysis, and Structure - Activity Relationship for a Series of Orally Active 3-Amino-6-Phenylpyridin-2-ones.
28. C. A. Veale, P. R. Bernstein, C. B. Bryant, C. Ceccarelli, J. R. Damewood, Jr., R. Earley, S. Feeney, B. C. Gomes, B. J. Kosmider, G. B. Steelman, R. M. Thomas, E. P. Vacek, J. C. Williams, D. J. Wolanin, and S. A. Woolson, J. Med. Chem., 38, 98 (1995). Non-Peptidic Inhibitors of Human Leukocyte Elastase. 5. Design, Synthesis, and X-Ray Crystallography of a Series of Orally Active 5-Aminopyrimidin-6-one-Containing Trifluoromethyl Ketones.
29. W. Bode, A.-Z. Wie, R. Huber, E. Meyer, J. Travis, and S. Neumann, EMBO J., 5, 2453 (1986). Crystal Structure of the Complex of Human Leukocyte Elastase (PMN Elastase) and the Third Domain of the Turkey Ovomucoid Inhibitor.
30. L. H. Takahashi, R. Radhakrishnan, R. E. Rosenfield Jr., E. F. Meyer Jr., D. A. Trainor, and M. Stein, J. Mol. Biol., 201, 423 (1988). X-Ray Diffraction Analysis of the Inhibition of Porcine Pancreatic Elastase by a Peptidyl Trifluoromethylketone.
31. The nomenclature system of Schechter and Berger for residues on either side of the scissile bond is used throughout this chapter. I. Schechter and A. Berger, Biochem. Biophys. Res. Commun., 27, 157 (1967). On the Size of the Active Site in Proteases. I. Papain.
32. AESOP is an in-house molecular mechanics program at Zeneca, Inc., Wilmington, DE 19897, derived in part from BIGSTRN-3 (QCPE 514): R. B. Nachbar, Jr., and K. Mislow, QCPE Bull., 6, 96 (1986).
33. J. A. McCammon and S. C. Harvey, Dynamics of Proteins and Nucleic Acids, Cambridge University Press, New York, 1987.
34. C. L. Brooks III, M. Karplus, and B. M. Pettitt, Proteins. A Theoretical Perspective of Dynamics, Structure and Thermodynamics, Wiley, New York, 1988.
35. W. F. van Gunsteren and P. K. Weiner, Eds., Computer Simulation of Bimolecular Systems. Theoretical and Experimental Applications, ESCOM, Leiden, 1989.
36. T. P. Lybrand, in Reviews in Computational Chemistry, K. B. Lipkowitz and D. B. Boyd, Eds., VCH Publishers, New York, 1990, Vol. 1, pp. 295-320. Computer Simulation of Biomolecular Systems using Molecular Dynamics and Free Energy Perturbation Methods.
37. U. C. Singh, P. Weiner, J. C. Caldwell, and P. A. Kollman, AMBER, University of California, San Francisco, 1989.
38. C. A. Veale, J. R. Damewood, Jr., G. B. Steelman, C. Bryant, B. Gomes, and J. Williams, J. Med. Chem., 38, 86 (1995). Non-Peptidic Inhibitors of Human Leukocyte Elastase. 4. Design, Synthesis, and In Vitro and In Vivo Activity of a Series of β-Carbolinone-Containing Trifluoromethyl Ketones.
39. P. D. Edwards, D. W. Andisik, A. M. Strimpler, B. Gomes, and P. A. Tuthill, J. Med. Chem., 39, 1112 (1996). Nonpeptidic Inhibitors of Human Neutrophil Elastase. 7. Design, Synthesis, and in Vitro Activity of a Series of Pyridopyrimidine-Containing Trifluoromethyl Ketones.
40. P. Kollman, Cheat. Rev., 93, 2395 (1993). Free Energy Calculations: Applications to Chemical and Biochemical Phenomena.
41. P. B. M. W. M. Timmermans and R. R. Wexler, Eds., Medicinal Chemistry of the Renin-Angiotensin System, Pharmaco Chemistry Library, 21, Elsevier, New York, 1994.
42. D. H. Rich, in Comprehensive Medicinal Chemistry. The Rational Design, Mechanistic Study & Therapeutic Application of Chemical Compounds, Enzymes and Other Molecular Targets, P. G. Sammes, Ed., Pergamon Press, New York, 1990, Vol. 2, pp. 414 ff. Peptidase Inhibitors.
43. V. Dhanaraj, C. Dealwis, C. Frazao, M. Badasso, B. L. Sibanda, I. J. Tickle, J. B. Cooper, H. P. C. Driessen, M. Newman, C. Aguilar, S. P. Wood, T. L. Blundell, P. M. Hobart, K. F. Geoghegan, M. J. Ammirati, D. E. Danley, B. A. O'Connor, and D. J. Hoover, Nature, 357, 466 (1992). X-Ray Analysis of Peptide Inhibitor Complexes Define the Structural Basis of Specificity for Human and Mouse Renins.
44. C. Hutchins and J. Greer, Crit. Rev. Biochem. Mol. Biol., 26, 77 (1991). Comparative Modeling of Proteins in the Design of Novel Renin Inhibitors.
45. B. Weidmann, Chimia, 45, 367 (1991). Renin-Inhibitoren-von 'Transition-State' Analogen und Peptidmimetika zu blutdrucksenkenden Wirkstoffen.
46. 2′ Sites.
47. E. A. Lunney and C. Humblet, in Medicinal Chemistry of the Renin-Angiotensin System, Pharmaco Chemistry Library, 21, P. B. M. W. M. Timmermans and R. R. Wexler, Eds., Elsevier, New York, 1994, pp. 73-101. Renin Inhibitor Design Through Molecular Modeling.
48. A. B. Smith III, T. P. Keenan, R. C. Holcomb, P. A. Sprengeler, M. C. Guzman, J. L. Wood, P. J. Carroll, and R. Hirschmann, J. Am. Chem. Soc., 114, 10672 (1992). Design, Synthesis, and Crystal Structure of a Pyrrolinone-Based Peptidomimetic Possessing the Conformation of a β-Strand: Potential Application to the Design of Novel Inhibitors of Proteolytic Enzymes.
49. A. B. Smith III, M. C. Guzman, P. A. Sprengeler, T. P. Keenan, R. C. Holcomb, J. L. Wood, P. J. Carroll, and R. Hirschmann, J. Am. Chem. Soc., 116, 9947 (1994). De Novo Design, Synthesis and X-Ray Crystal Structures of Pyrrolinone-Based β-Strand Peptidomimetics.
50. A. B. Smith III, R. Hirschmann, A. Pasternak, R. Akaishi, M. C. Guzman, D. R. Jones, T. P. Keenan, P. A. Sprengeler, P. L. Drake, E. A. Emini, M. K. Holloway, and W. A. Schleif, J. Med. Chem., 37, 215 (1994). Design and Synthesis of Peptidomimetic Inhibitors of HIV-1 Protease and Renin. Evidence for Improved Transport.
51. The reader is referred to continuing work, published after the time period covered by this review, from the following paper: A. B. Smith III, R. Akaishi, D. R. Jones, T. P. Keenan, M. C. Guzman, R. C. Holcomb, P. A. Sprengeler, J. L. Wood, R. Hirschmann, and M. K. Holloway, Biopolymers, 37, 29 (1995). Design and Synthesis of Nonpeptide Peptidomimetic Inhibitors of Renin.
52. J. R. Luly, N. BaMaung, J. Soderquist, A. K. L. Fung, H. Stein, H. D. Kleinert, P. A. Marcotte, D. A. Egan, B. Bopp, I. Merits, G. Bolis, J. Greer, T. J. Perun, and J. J. Plattner, J. Med. Chem., 31, 2264 (1988). Renin Inhibitors. Dipeptide Analogues of Angiotensinogen Utilizing a Dihydroxyethylene Transition-State Mimic at the Scissile Bond to Impart Greater Inhibitory Potency.
53. K. Izuka, T. Kamijo, T. Kubota, K. Akahane, H. Umeyama, and Y. Kiso. J. Med. Chem., 31, 701 (1988). New Human Renin Inhibitors Containing an Unnatural Amino Acid, Norstatine.
54. F. Mohamadi, N. G. J. Richards, W. C. Guida, R. Liskamp, M. Lipton, C. Caufield, G. Chang, T. Hendrickson, and W. C. Still, J. Comput. Chem., 11, 440 (1990). MacroModel - An Integrated Software System for Modeling Organic and Bioorganic Molecules Using Molecular Mechanics.
55. 1′ Dipeptide Mimetics.
56. D. H. Rich, in Comprehensive Medicinal Chemistry. The Rational Design, Mechanistic Study & Therapeutic Application of Chemical Compounds, Enzymes and Other Molecular Targets, P. G. Sammes, Ed., Pergamon Press, New York, 1990, Vol. 2, pp. 400 ff. Peptidase Inhibitors.
57. G. A. Flynn, E. L. Giroux, and R. C. Dage, J. Am. Chem. Soc., 109, 7914 (1987). An Acyl-Iminium Ion Cyclization Route to a Novel Conformationally Restricted Dipeptide Mimic: Applications to Angiotensin-Converting Enzyme Inhibition.
58. P. B. M. W. M. Timmermans, P. C. Wong, A. T. Chiu, W. F. Herblin, P. Benfield, D. J. Carini, R. J. Lee, R. R. Wexler, J. A. M. Saye, and R. D. Smith, Pharm. Rev., 45, 205 (1993). Angiotensin II Receptors and Angiotensin II Receptor Antagonists.
59. M. I. Steinberg, S. A. Wiest, and A. D. Palkowitz, Cardiovasc. Drug Rev., 11, 312 (1993). Nonpeptide Angiotensin II Receptor Antagonists.
60. R. H. Bradbury, B. B. Masek, and D. A. Roberts, in Medicinal Chemistry of the Renin-Angiotensin System, Pharmaco Chemistry Library, 21, P. B. M. W. M. Timmermans and R. R. Wexler, Eds., Elsevier, New York, 1994, pp. 157-174. Angiotensin II Receptor Antagonists: Molecular Modeling.
61. Y. Furukawa, S. Kishimoto, and K. Nishikawa, U.S. Patents 4,340,598 and 4,355,040 (1982).
62. J. V. Duncia, A. T. Chiu, D. J. Carini, G. B. Gregory, A. L. Johnson, W. A. Price, G. J. Wells, P. C. Wong, J. C. Calabrese, and P. B. M. W. M. Timmermans, J. Med. Chem., 33, 1312 (1990). The Discovery of Potent Nonpeptide Angiotensin II Receptor Antagonists: A New Class of Potent Antihypertensives.
63. R. Smeby and S. Fermandjian, in Chemistry and Biochemistry of Amino Acids, Vol. 5, Peptides and Proteins, B. Weinstein, Ed., Dekker, New York, 1978, pp. 117-162. Conformation of Angiotensin II.
64. J. V. Duncia, D. J. Carini, A. T. Chiu, A. L. Johnson, W. A. Price, P. C. Wong, R. R. Wexler, and P. B. M. W. M. Timmermans, Med. Res. Rev., 12, 149 (1992). The Discovery of DuP 753, a Potent, Orally Active Nonpeptide Angiotensin II Receptor Antagonist.
65. See, for example, D. J. Carini, J. V. Duncia, P. E. Aldrich, A. T. Chiu, A. L. Johnson, M. E. Pierce, W. A. Price, J. B. Santella III, G. J. Wells, R. R. Wexler, P. C. Wong, S.-E. Yoo, and P. B. M. W. M. Timmermans, J. Med. Chem., 34, 2525 (1991). Nonpeptide Angiotensin II Receptor Antagonists: The Discovery of a Series of N-(Biphenylylmethyl)imidazoles as Potent, Orally Active Antihypertensives.
66. D. J. Carini, R. J. Ardecky, C. L. Ensinger, J. R. Pruitt, R. R. Wexler, P. C. Wong, S.-M. Huang, B. J. Aungst, and P. B. M. W. M. Timmermans, Dioorg. Med. Chem. Lett., 4, 63 (1994). Nonpeptide Angiotensin II Receptor Antagonists: The Discovery of DMP 581 and DMP 811, and references therein.
67. J. Weinstock, R. M. Keenan, J. Samanen, J. Hempel, J. A. Finkelstein, R. G. Franz, D. E. Gaitanopoulos, G. R. Girard, J. G. Gleason, D. T. Hill, T. M. Morgan, C. E. Peishoff, N. Aiyar, D. P. Brooks, T. A. Fredrickson, E. H. Ohlstein, R. R. Ruffolo Jr., E. J. Stack, A. C. Sulpizio, E. F. Weidley, and R. M. Edwards, J. Med. Chem. 34, 1514 (1991). 1-(Carboxybenzyl)imidazole-5-acrylic Acids: Potent and Selective Angiotensin II Receptor Antagonists.
68. R. M. Keenan, J. Weinstock, J. A. Finkelstein, R. G. Franz, D. E. Gaitanopoulos, G. R. Girard, D. T. Hill, T. M. Morgan, J. M. Samanen, J. C. Hempel, D. Eggleston, N. Aiyar, E. Griffin, E. H. Ohlstein, E. J. Stack, E. F. Weidley, and R. M. Edwards, J. Med. Chem., 35, 3858 (1992). Imidazole-5-Acrylic Acids: Potent Nonpeptide Angiotensin II Receptor Antagonists Designed Using a Novel Peptide Pharmacophore Model.
69. J. M. Samanen, C. E. Peishoff, R. M. Keenan, and J. Weinstock, Bioorg. Med. Chem. Lett., 3, 909 (1993). Refinement of a Molecular Model of Angiotensin II (AII) Employed in the Discovery of Potent Nonpeptide Antagonists.
70. R. M. Keenan, J. Weinstock, J. A. Finkelstein, R. G. Franz, D. E. Gaitanopoulos, G. R. Girard, D. T. Hill, T. M. Morgan, J. M. Samanen, C. E. Peishoff, L. M. Tucker, N. Aiyar, E. Griffin, E. H. Ohlstein, E. J. Stack, E. F. Weidley and R. M. Edwards, J. Med. Chem., 36, 1880 (1993). Potent Nonpeptidic Angiotensin II Receptor Antagonists. 2. 1-(Carboxybenzyl)imidazole-5-acrylic Acids.
71. Tripos, Inc., St. Louis, MO 63144.
72. G. J. Moore, Trends Pharmacol. Sci., 15, 124 (1994). Designing Peptide Mimetics.
73. P. Bühlmayer, P. Furet, L. Criscione, M. de Gasparo, S. Whitebread, T. Schmidlin, R. Lattmann, and J. Wood, Bioorg. Med. Chem. Lett., 4, 29 (1994). Valsartan, a Potent, Orally Active Angiotensin II Antagonist Developed from the Structurally New Amino Acid Series.
74. A. D. Palkowitz, M. I. Steinberg, K. J. Thrasher, J. K. Reel, K. L. Hauser, K. M. Zimmerman, S. A. Wiest, C. A. Whitesitt, R. L. Simon, W. Pfeifer, S. L. Lifer, D. B. Boyd, C. J. Barnett, T. M. Wilson, J. B. Deeter, K. Takeuchi, R. E. Ritey, W. D. Miller, and W. S. Marshall, J. Med. Chem., 37, 4508 (1994). Structural Evolution and Pharmacology of a Novel Series of Triacid Angiotensin II Receptor Antagonists.
75. D. B. Boyd, A. D. Palkowirz, J. Thrasher, K. L. Hauser, C. A. Whitesitt, J. K. Reel., R. L. Simon, W. Pfeifer, S. L. Lifer, K. Takeuchi, V. Vasudevan, A. D. Kossoy, J. B. Deeter, M. I. Steinberg, K. M. Zimmerman, S. A. Wiest, and W. S. Marshall, in Comptiter-Aided Molecular Design. Applications in Agrochemicals, Materials, and Pharmaceutical, C. H. Reynolds, M. K. Holloway, and H. K. Cox, Eds., American Chemical Society, Washington, DC, 1995, pp. 14-35. Molecular Modeling and Quantitative Structure-Activity Relationship Studies in Pursuit of Highly Potent Substituted Octanoamide Angiotensin II Receptor Antagonists.
76. D. B. Boyd (IUPUI), personal communication, 1995.
77. K. Prendergast, K. Adams, W. J. Greenlee, R. B. Nachbar, A. A. Patchett, and D. J. Underwood, J. Comput.-Aided Mol. Design, 8, 491 (1994). Derivation of a 3D Pharmacophore Model for the Angiotensin-II Site One Receptor.
78. E. G. Erdös and R. A. Skidgel, FASEB J., 3, 145 (1989). Neutral Endopeptidase 24.11 (Enkephalinase) and Related Regulators of Peptide Hormones.
79. G. A. Flynn, D. W. Beight, S. Mehdi, J. R. Koehl, E. L. Giroux, J. F. French, P. W. Hake, and R. C. Dage,J. Med. Chem., 36, 2420 (1993). Application of a Conformationally Restricted Phe-Leu Dipeptide Mimetic to the Design of a Combined Inhibitor of Angiotensin-I Converting Enzyme and Neutral Endopeptidase 24.11.
80. BIOSYM Technologies, San Diego, CA 92121.
81. M.-C. Fournié-Zaluski, P. Coric, S. Turcaud, N. Rousselet, W. Gonzalez, B. Barbe, I. Pham, N. Jullian, J.-B. Michel, and B. P. Roques, J. Med. Chem., 37, 1070 (1994). New Dual Inhibitors of Neutral Endopeptidase and Angiotensin-Converting Enzyme: Rational Design, Bioavailability, and Pharmacological Responses in Experimental Hypertension. See also references therein.
82. See, for example, C. Peng, B. K. Ho, T. W. Chang, and N. T. Chang, J. Virol., 63, 2550 (1989). Role of Human Immunodeficiency Virus Type 1-Specific Protease in Core Protein Maturation and Viral Infectivity.
83. M. Miller, J. Schneider, B. K. Sathyanarayan, M. V. Toth, G. R. Marshall, L. Clawson, L. Selk, S. B. H. Kent, and A. Wlodawer, Science, 246, 1149 (1989). Structure of a Complex of Synthetic HIV-1-Protease with a Substrate-Based Inhibitor at 2.3 Å Resolution.
84. A. L. Swain, M. M. Miller, J. Green, D. H. Rich, J. Schneider, S. B. H. Kent, and A. Wlodawer, Proc. Natl. Acad. Sci., U.S.A., 87, 8805 (1990). X-Ray Cristallographic Structure of a Complex Between a Synthetic Protease of Human Immunodeficiency Virus 1 and a Substrate-Based Hydroxyethylamine Inhibitor.
85. M. Clare, Perspect. Drug Discovery Design, 1, 49 (1993). HIV Protease: Structure-Based Design.
86. See, for example, R. L. Desjarlais, and J. S. Dixon, J. Comput.-Aided Mol. Design, 8, 231 (1994). A Shape- and Chemistry-Based Docking Method and its Use in the Design of HIV-1 Protease Inhibitors.
87. M. A. McCarrick and P. Kollman, Methods Enzymol, 241, 370 (1994). Use of Molecular Dynamics and Free Energy Perturbation Calculations in Anti-Human Immunodeficiency Virus Drug Design.
88. R. A. Smith, P. J. Coles, J. J. Chen, V. J. Robinson, I. D. MacDonald, J. Carrière, and A. Krantz, Bioorg. Med. Chem. Lett., 4, 2217 (1994). Design, Synthesis and Activity of Conformationally Constrained Macrocyclic Peptide-Based Inhibitors of HIV Protease.
89. M. R. Reddy, M. D. Varney, V. Kalish, V. N. Viswanadhan, and K. Appelt, J. Med. Chem., 37, 1145 (1994). Calculation of Relative Differences in the Binding Free Energies of HIV-1 Protease Inhibitors: A Thermodynamic Cycle Perturbation Approach.
90. M. D. Varney, K. Appelt, V. Kalish, M. R. Reddy, J. Tatlock, C. L. Palmer, W. H. Romines, B.-W. Wu, and L. Musick, J. Med. Chem., 37, 2274 (1994). Crystal-Structure-Based Design and Synthesis of Novel C-Terminal Inhibitors of HIV Protease.
91. G. B. Dreyer, B. W. Metcalf, T. A. Tomaszek, T. J. Carr, A. C. Chandler III, L. Hyland, S. A. Fakhoury, V. W. Magaard, M. L. Moore, J. E. Strickler, C. Debouck, and T. D. Meek, Proc. Natl. Acad. Sci. U.S.A., 86, 9752 (1989). Inhibition of Human Immunodeficiency Virus 1 Protease In Vitro: Rational Design of Substrate Analogue Inhibitors.
92. M. J. S. Dewar, E. G. Zoebisch, E. F. Healy, and J. J. P. Stewart, J. Am. Chem. Soc., 107, 3902 (1985). A New General Quantum Mechanical Molecular Model.
93. See, for example, M. R. Reddy and M. Berkowitz, Chem. Phys. Lett., 155, 173 (1989). The Dielectric Constant of SPCJE Water. See also references therein.
94. P. Y. S. Lam, P. K. Jadhav, C. J. Eyermann, C. N. Hodge, Y. Ru, L. T. Bacheler, J. L. Meek, M. J. Otto, M. M. Rayner, Y. N. Wong, C.-H. Chang, P. C. Weber, D. A. Jackson, T. R. Sharpe, and S. Erickson-Viitanen, Science, 263, 380 (1994). Rational Design of Potent, Bioavailable, Nonpeptide Cyclic Ureas as HIV Protease Inhibitors.
95. F. H. Allen and O. Kennard, Chem. Design Autant. News, 8, 31 (1993). 3D Search and Research Using the Cambridge Structural Database.
96. MDL Information Systems, Inc., San Leandro, CA 94577.
97. 2 Symmetric Inhibitor Complexed to HIV-1 Protease.
98. R. S. Randad, W. Pan, S. V. Gulnik, S. Burt, and J. W. Erickson, Bioorg. Med. Chem. Lett., 4, 1247 (1994). De Novo Design of Nonpeptidic HIV-1 Protease Inhibitors: Incorporation of Structural Water.
99. B. L. Podlogar, R. A. Farr, D. Friedrich, C. Tarnus, E. W. Huber, R. J. Cregge, and D. Schirlin, J. Med. Chem., 37, 3684 (1994). Design, Synthesis, and Conformational Analysis of a Novel Macrocyclic HIV-Protease Inhibitor.
100. 3-Ligands.
101. 1′ Phenyl Substituents: X-Ray Crystal Structure Assisted Design.
102. T. A. Halgren, Merck Sharp and Dohme Research Laboratories, Rahway, NJ. OPTIMOL uses partial charges on atoms and lacks unshared pairs of electrons on certain nitrogen and oxygen atoms. See also, M. K. Holloway, J. M. Wai, T. A. Halgren, P. M. D. Fitzgerald, J. P. Vacca, B. D. Dorsey, R. B. Levin, W. J. Thompson, L. J. Chen, S. J. deSolms, N. Gaffin, A, K. Ghosh, E. A. Giuliani, S. L. Graham, J. P. Guare, R. W. Hungate, T. A. LyIe, W. M. Sanders, T. J. Tucker, M. Wiggins, C. M. Wiscount, O. W. Woltersdorf, S. D. Young, P.L. Darke, and J. A. Zugay, J. Med. Chem., 38, 305 (1995). A Priori Prediction of Activity for HIV-1 Protease Inhibitors Employing Energy Minimization in the Active Site.
103. 2 Ligands for HIV-1 Protease Inhibitors.
104. B. M. Kim, J. P. Vacca, P. M. D. Fitzgerald, P. L. Darke, M. K. Holloway, J. P. Guare, C. M. Hanifin, D. J. Arford-Bickerstaff, J. A. Zugay, J. M. Wai, P. S. Anderson, and J. R. Huff, Bioorg. Med. Chem. Lett., 4, 2199 (1994). Novel Conformationally Constrained HIV-I Protease Inhibitors: Rational Design, Enzyme Inhibition, and X-Ray Structure of an Enzyme-Inhibitor Complex.
105. B. D. Dorsey, R. B. Levin, S. L. McDaniel, J. P. Vacca, J. P. Guare, P. L. Darke, J. A. Zugay, E. A. Emini, W. A. Schleif, J. C. Quintero, J. H. Lin, I.-W. Chen, M. K. Holloway, P. M. D. Fitzgerald, M. G. Axel, D. Ostovic, P. S. Anderson, and J. R. Huff, J. Med. Chem., 37, 3443 (1994). L-735,524: The Design of a Potent and Orally Bioavailable HIV Protease Inhibitor.
106. See also, M. K. Holloway and J. M. Wai, in Computer-Aided Molecular Design: Applications in Agrochemicals, Materials, and Pharmaceutical. (A symposium at the 207th American Chemical Society National Meeting, March 13-17, 1994, San Diego, CA), C. H. Reynolds, M. K. Holloway, and H. K. Cox, Eds., American Chemical Society, Washington, DC, 1995, pp. 36-50. Structure-Based Design of Human Immunodeficiency Virus-1 Protease Inhibitors: Correlating Calculated Energy with Activity.
107. P. M. D. Fitzgerald, Merck Research Laboratories, unpublished results.
108. 2′ Amide Bond Isostere.
109. S. S. Abdel-Meguid, B. W. Metcalf, T. J. Carr, P. Demarsh, R. L. Desjarlais, S. Fisher, D. W. Green, L. Ivanoff, D. M. Lambert, K. H. M. Murthy, S. R. Petteway Jr., W. J. Pitts, T. A. Tomaszek Jr., E. Winborne, B. Zhao, G. B. Dryer, T. D. Meek, Biochemistry, 33, 1671 (1994). An Orally Bioavailable HIV-I Protease Inhibitor Containing an Imidazole-Derived Peptide Bond Replacement: Crystallographic and Pharmacokinetic Analysis.
110. R. E. Babine, N. Zhang, S. R. Schow, Z. Xu, R. A. Byrn, R. C. Hastings, M. F. Semmelhack, M. W. Wick, and S. S. Kerwar, Bioorg. Med. Chem. Lett. 4, 583 (1994). Design, Structure Activity and X-Ray Crystallographic Studies of Pseudo-Symmetrical Nonpeptidyl HIV-I Protease Inhibitors.
111. H. Nakanishi, S. Ramurthy, A. Raktabutr, R. Shen, and M. Kahn, Gene, 137, 51 (1993). Peptidomimetics of the Immunoglobulin Supergene Family - A Review.
112. Q. J. Sattentau and R. A. Weiss, Cell, 52, 631 (1988). The CD4 Antigen: Physiological Ligand and HIV Receptor.
113. J. Wang, Y. Yan, T. P. J. Garrett, J. Lui, D. W. Rodgers, R. L. Garlick, G. E. Tarr, Y. Husain, E. L. Reinherz, and S. C. Harrison, Nature, 348, 411 (1990). Atomic Structure of a Fragment of Human CD4 Containing Two Immunoglobulin-Like Domains.
114. S.-E. Ryu, P. D. Kwong, A. Truneh, T. G. Porter, J. Arthos, M. Rosenberg, X. Dai, N.-H. Xuong, R. Axel, R. W. Sweet, and W. A. Hendrickson, Nature, 348, 419 (1990). Crystal Structure of an HIV-Binding Recombinant Fragment of Human CD4.
115. S. Chen, R. A. Chrusciel, H. Nakanishi, A. Raktabutr, M. E. Johnson, A. Sato, D. Veiner, J. Hoxie, H. U. Saragovi, M. I. Greene, and M. Kahn, Proc. Natl. Acad. Sci. U.S.A., 89, 5872 (1992). Design and Synthesis of a CD4 β-Turn Mimetic That Inhibits Human Immunodeficiency Virus Envelope Glycoprotein gp120 Binding and Infection of Human Lymphocytes.
116. W. C. Still, A. Tempczyk, R. C. Hawley, and T. Hendrickson, J. Am. Chem. Soc., 112, 6127 (1990). Semianalytical Treatment of Solvation for Molecular Mechanics and Dynamics.
117. B. P. Morgan, D. R. Holland, B. W. Matthews, and P. A. Bartlett, J. Am. Chem. Soc., 116, 3251 (1994). Structure-Based Design of an Inhibitor of the Zinc Peptidase Thermolysin.
118. S. L. Mayo, B. D. Olafson, and W. A. Goddard III, J. Phys. Chem., 94, 8897 (1990). A Generic Force Field for Molecular Simulations.
119. S. F. Martin, C. J. Oalmann, and S. Liras, Tetrahedron, 49, 3521 (1993). Cyclopropanes as Conformationally Restricted Peptide Isosteres. Design and Synthesis of Novel Collagenase Inhibitors.
120. J. W. Pflugrath, G. Wiegand, R. Huber, and L. Vértesy, J. Mol. Biol. 189, 383 (1986). Crystal Structure Determination, Refinement, and the Molecular Model of the α-Amylase Inhibitor HOE-467A.
121. A. D. Kline, W. Braun, and K. Wüthrich, J. Mol. Biol., 204, 675 (1988). Determination of the Complete Three-Dimensional Structure of the á-Amylase Inhibitor Tendamistat in Aqueous Solution by Nuclear Magnetic Resonance and Distance Geometry.
122. F. A. Etzkorn, T. Guo, M. A. Lipton, S. D. Goldberg, and P. A. Bartlett, J. Am. Chem. Soc., 116, 10412 (1994). Cyclic Hexapeptides and Chimeric Peptides and Mimics of Tendamistat.
123. P. A. Bartlett, G. T. Shea, S. J. Telfer, and S. Waterman, in Molecular Recognition: Chemical and Biological Problems, S. M. Roberts, Ed., Royal Society of Chemistry, London, 1989, pp. 182-196. CAVEAT: A Program to Facilitate the Structure-Derived Design of Biologically Active Molecules.
124. G. Lauri and P. A. Bartlett, J. Compitt.-Aided Mol. Design, 8, 51 (1994). CAVEAT: A Program to Facilitate the Design of Organic Molecules.
125. V. Austel, F. Himmelsbach, and T. Müller, Drags Future, 19, 757 (1994). Nonpeptidic Fibrinogen Receptor Antagonists.
126. C. E. Peishoff, F. E. Ali, J. W. Bean, R. Calvo, C. A. D'Ambrosio, D. S. Eggleston, S. M. Hwang, T. P. Kline, P. F. Koster, A. Nichols, D. Powers, T. Romoff, J. M. Samanen, J. Stadel, J. A. Vasko, and K. D. Kopple, J. Med. Chem., 35, 3692 (1992). Investigation of Conformational Specificity at GPIIb/IIIa: Evaluation of Conformationally Constrained RGD Peptides.
127. J. F. Callahan, J. W. Bean, J. L. Burgess, D. S. Eggleston, S. M. Hwang, K. D. Kopple, P. F. Koster, A. Nichols, C. E. Peishoff, J. M. Samanen, J. A. Vasko, A. Wong, and W. F. Huffman, J. Med. Chem., 35, 3970 (1992). Design and Synthesis of a C7 Mimetic for the Predicted γ-Turn Conformation Found in Several Constrained RGD Antagonists.
128. T. W. Ku, F. E. Ali, L. S. Barton, J. W. Bean, W. E. Bondinell, J. L. Burgess, J. F. Callahan, R. R. Calvo, L. Chen, D. S. Eggleston, J. G. Gleason, W. F. Huffman, S. M. Hwang, D. R. Jakas, C. B. Karash, R. M. Keenan, K. D. Kopple, W. H. Miller, K. A. Newlander, A. Nichols, M. F. Parker, C. E. Peishoff, J. M. Samanen, I. Uzinskas, and J. W. Venslavsky, J. Am. Chem. Soc., 115, 8861 (1994). Direct Design of a Potent Non-Peptide Fibrinogen Receptor Antagonist Based on the Structure and Conformation of a Highly Constrained Cyclic RGD Peptide.
129. The reader is referred to continuing work from this group, published after the time period covered by this review. T. W. Ku, W. H. Miller, W. E. Bondinell, K. F. Erhard, R. M. Keenan, A. J. Nichols, C. E. Pieshoff, J. M. Samanen, A. S. Wong, and W. F. Huffman, J. Med. Chem., 38, 9 (1995). Potent Nonpeptide Fibrinogen Receptor Antagonists Which Present an Alternative Pharmacophore.
130. R. S. McDowell, T. R. Gadek, P. L. Barker, D. J. Burkick, K. S. Chan, C. L. Quan, N. Skelton, M. Struble, E. D. Thorsett, M. Tischler, J. Y. K. Tom, T. R. Webb, and J. P. Burnier, J. Am. Chem. Soc., 116, 5069 (1994). From Peptide to Non-Peptide. 1. The Elucidation of a Bioactive Conformation of the Arginine-Glycine-Aspartic Acid Recognition Sequence.
131. R. S. McDowell, B. K. Blackburn, T. R. Gadek, L. R. McGee, T. Rawson, M. E. Reynolds, K. D. Robarge, T. C. Somers, E. D. Thorsett, M. Tischler, R. R. Webb II, and M. C. Venuti, J. Am. Chem. Soc., 116, 5077 (1994). From Peptide to Non-Peptide. 2. The De Novo Design of Potent, Non-Peptidal Inhibitors of Platelet Aggregation Based on a Benzodiazepinedione Scaffold.
132. See Reference 124 for a discussion of this methodology in detail.
133. J. M. Blaney, G. M. Crippen, A. Dearing, and J. S. Dixon, QCPE, Indiana University, Bloomington IN 47405. DGEOM, Program 590. See also J. M. Blaney and J. S. Dixon, in Reviews in Computational Chemistry, K. B. Lipkowitz and D. B. Boyd, Eds., VCH Publishers, New York, 1994, Vol. 5, pp. 299-335. Distance Geometry in Molecular Modeling.
134. G. D. Hartman, M. S. Egbertson, W. Halczenko, W. L. Laswell, M. E. Duggan, R. L. Smith, A. M. Naylor, P. D. Manno, R. J. Lynch, G. Zhang, C. T.-C. Chang, and R. J. Gould, J. Med. Chem., 35, 4640 (1992). Non-Peptide Fibrinogen Receptor Antagonists. 1. Discovery and Design of Exosite Inhibitors.
135. J. A. Zablocki, M. Miyano, S. N. Rao, S. Panzer-Knodle, N. Nicholson, and L. Feigen, J. Med. Chem., 35, 4914 (1992). Potent Inhibitors of Platelet Aggregation Based Upon the Arg-Gly-Asp-Phe Sequence of Fibrinogen. A Proposal on the Nature of the Binding Interactions Between the Asp-Carboxylate of RGDX Mimetics and the Platelet GP IIb/IIIa Receptor.
136. J. A. Zablocki, M. Miyano, R. B. Garland, D. Pireh, L. Schretzman, S. N. Rao, R. J. Lindmark, S. G. Panzer-Knodle, N. S. Nicholson, B. B. Taite, A. K. Salycrs, L. W. King, J. G. Campion, and L. P. Feigen,J. Med. Chem., 36, 1811 (1993). Potent In Vitro and In Vivo Inhibitors of Platelet Aggregation Based
137. 2 Torsional Terms.
138. Gaussian, Inc., Pittsburgh, PA 15106.
139. W. J. Hehre, L. Radom, P. v. R. Scheleyer, and J. A. Pople, Ab lnitio Molecular Orbital Theory; Wiley, New York, 1986.
140. R. Hershkoviz, N. Greenspoon, Y. A. Mekori, R. Hadari, R. Alon, G. Kapustina, and O. Lider, Clin. Exp. Immunol., 95, 270 (1994). Inhibition of CD4+ T Lymphocyte Binding to Fibronectin and Immune-Cell Accumulation in Inflammatory Sites by Nonpeptide Mimics of Arg-Gly-Asp.
141. R. Hirschmann, P. A. Sprengeler, T. Kawasaki, J. W. Leahy, W. C. Shakespeare, and A. B. Smith III, Tetrahedron, 49, 3665 (1993). The Versatile Steroid Nucleus: Design and Synthesis of a Peptidomimetic Employing This Novel Scaffold.
142. R. Hirschmann, P. A. Sprengeler, T. Kawasaki, J. W. Leahy, W. C. Shakespeare, and A. B. Smith III,J. Am. Chem. Soc. 114, 9699 (1992). The First Design and Synthesis of a Steroidal Peptidomimetic. The Potential Value of Peptidomimetics in Elucidating the Bioactive Conformation of Peptide Ligands.
143. H. Nakanishi, R. A. Chrusciel, R. Shen, S. Bertenshaw, M. E. Johnson, T. J. Rydel, A. Tulinsky, and M. Kahn, Proc. Natl. Acad. Sci. U.S.A., 89, 1705 (1992). Peptide Mimetics of the Thrombin-Bound Structure of Fibrinopeptide A.
144. T. J. Rydel, K. G. Ravichandran, A. Tulinsky, W. Bode, R. Huber, C. Roitsch, and J. W. Fenton II, Science, 249, 277 (1990). The Structure of a Complex of Recombinant Hirudin and Human Alpha-Thrombin.
145. R. Huber, and W. Bode, Acc. Chem. Res., 111 (1978). Structural Basis of Activation and Action of Trypsin. See also references therein.
146. T.-P. Wu, V. Yee, A. Tulinsky, R. A. Chrusciel, H. Nakanishi, R. Shen, C. Priebe, and M. Kahn, Protein Eng., 6, 471 (1993). The Structure of a Designed Peptidomimetic Inhibitor Complex of α-Thrombin.
147. J. D. Elliott, M. A. Lago, R. D. Cousins, A. Gao, J. D. Leber, K. F. Erhard, P. Nambi, N. A. Elshourbagy, C. Kumar, J. A. Lee, J. W. Bean, C. W. DeBrosse, D. S. Eggleston, D. P. Brooks, G. Feuerstein, R. R. Ruffolo Jr., J. Weinstock, J. G. Gleason, C. E. Peishoff, and E. H. Ohlstein, J. Med. Chem., 37, 1553 (1994). 1,3-Diarylindan-2-carboxylic Acids, Potent and Selective Non-Peptide Endothelin Receptor Antagonists.
148. E. H. Ohlstein, P. Nambi, S. A. Douglas, R. M. Edwards, M. Gellai, A. Lago, J. D. Leber, R. D. Cousins, A. Gao, J. S. Frazee, C. E. Peishorf, J. W. Bean, D. S. Eggleston, N. A. EIshourbagy, C. Kumar, J. A. Lee, T.-L. Yue, C. Louden, D. P. Brooks, J. Weinstock, G. Feuerstein, G. Poste, R. R. Ruffolo Jr., J. G. Gleason, and J. D. Elliott, Froc. Natl. Acad. Sci. U.S.A., 91, 8052 (1994). SB 209670, A Rationally Designed Potent Nonpeptide Endothelin Receptor Antagonist.
149. Details are to be published.
150. M. Ihara, K. Noguchi, T. Saeki, T. Fukuroda, S. Tsuchida, S. Kimura, T. Fukami, K. Ishikawa, M. Nishikibe, and M. Yano, Life. Sci., 50, 247 (1992). Biological Profiles of Highly Potent Novel Endothelin Antagonists Selective for the ETA Receptor.
151. J. W. Bean, C. E. Peishoff, and K. D. Kopple, Int. J. Peptide Protein Res., 44, 223 (1994). Conformations of Cyclic Pentapeptide Endothelin Receptor Antagonists.
152. R. F. Nutt, C. D. Colton, R. Saperstein, and D. F. Veber, in Somatostatin, S. Reichlin, Ed., Plenum Press, New York, 1987, pp. 83-88. Side Chain Conformation of Somatostatin Analogs when Bound to Receptors.
153. R. Hirschmann, K. C. Nicolaou, S. Pietranico, J. Salvino, E. M. Leahy, P. A. Sprengeler, G. Fürst, A. B. Smith III, C. D. Strader, M. A. Cascieri, M. R. Candelore, C. Donaldson, W. Vale, and L. Maechler,J. Am. Chem. Soc., 114, 9217 (1992). Nonpeptidal Peptidomimetics with a β-D-Glucose Scaffolding. A Partial Somatostatin Agonist Bearing a Close Structural Relationship to a Potent, Selective Substance P Antagonist.
154. R. Hirschmann, K. C. Nicolaou, S. Pietranico, E. M. Leahy, J. Salvino, B. Arison, M. A. Cichy, P. G. Spoors, W. C. Shakespeare, P. A. Sprengeler, P. Hamley, A. B. Smith III, T. Reisine, K. Raynor, L. Maechler, C. Donaldson, W. Vale, R. M. Freidinger, M. A. Cascieri, and C. D. Strader,J. Am. Chem. Soc., 115, 12550 (1993). De Novo Design and Synthesis of Somatostatin Non-Peptide Peptidomimetics Utilizing β-D-Glucose as a Novel Scaffolding.
155. C. Papageorgiou, R. Haltiner, C. Burns, and T. J. Petcher, Bioorg. Med. Chem. Lett., 2, 135 (1992). Design, Synthesis, and Binding Affinity of a Nonpeptide Mimic of Somatostatin.
156. F. Momany, R. F. McGuire, A. W. Burgess, and H. A. Scheraga,J. Phys. Chem., 79, 2361 (1975). Energy Parameters in Polypeptides. VII. Geometric Parameters, Partial Atomic Charges, Nonbonded Interactions, Hydrogen Bond Interactions, and Intrinsic Torsional Potentials for the Naturally Occurring Amino Acids.
157. See also M. J. Browman, L. M. Carruthers, K. L. Kashuba, F. A. Momany, M. S. Pottle, S. P. Rosen, S. M. Rumsey, G. F. Endres, and H. A. Scheraga, QCPE, 11, 286 (1975); QCPE, Bloomington, IN.
158. W. R. Schoen, M. J. Wyvratt Jr., and R. G. Smith, Annu. Rep. Med. Chem. 28, 177 (1993). Growth Hormone Secretagogues.
159. W. R. Schoen, J. M. Pisano, K. Prendergast, M. J. Wyvratt Jr., M. H. Fisher, K. Cheng, W. W.-S. Chan, B. Butler, R. G. Smith, and R. G. Ball, J. Med. Chem., 37, 897 (1994). A Novel 3-Substituted Benzazepinone Growth Hormone Secretagogue (L-692,429).
160. Molecular Simulations, Inc., San Diego, CA.
161. B. R. Brooks, R. E. Bruccoleri, B. D. Olafson, D. J. States, S. Swaminathan, and M. Karplus, J. Compttt. Chem., 4, 187 (1983). CHARMM: A Program for Macromolecular Energy Minimization and Dynamics Calculations.
162. S. Kearsley and G. Smith, Tetrahedron Compttt. Methodol., 3, 615 (1992). An Alternative Method for the Alignment of Molecular Structures: Maximizing Electrostatic and Steric Overlap.
163. P. D. Williams, M. G. Bock, R. D. Tung, V. M. Garsky, D. S. Perlow, J. M. Erb, G. F. Lundell, N. P. Could, W. L. Whitter, J. B. Hoffman, M. J. Kaufman, B. V. Clineschmidt, D. J. Pettibone, R. M. Freidinger, and D. F. Veber,J. Med. Chem. 35, 3905 (1992). Development of a Novel Class of Cyclic Hexapeptide Oxytocin Antagonists Based on a Natural Product.
164. P. D. Williams, P. S. Anderson, R. G. Ball, M. G. Bock, L. Carroll, S.-H. L. Chiu, B. V. Clineschmidt, J. C. Culberson, J. M. Erb, B. E. Evans, S. L. Fitzpatrick, R. M. Freidinger, M. J. Kaufman, G. F. Lundell, J. S. Murphy, J. M. Pawluczyk, D. S. Perlow, D. J. Pettibone, S. M. Pitzenberger, K. L. Thompson, and D. F. Veber, J. Med. Chem., 37, 565 (1994). 1-(((7,7-Dimethyl-2(S)-2(S)-amino-4-(methylsulfonyl)butyramido)bicyclo[2.2.1]- heptan-1(S)-yl)methyl)sulfonyl)-4-(2-methylphenyl)piperazine (L-3 68,899): An Orally Bioavailable, Non-Peptide Oxytocin Antagonist with Potential Utility for Managing Preterm Labor.
165. T. A. Halgren, J. Comput. Chem., 17, 490 (1996). Merck Molecular Force Field. I. Basis, Form, Scope, Parameterization, and Performance of MMFF94. See also following papers of series.
166. SQUEAL (Structural and Qualitative Electrostatic ALignment) is an unpublished variation of SEAL. M. D. Miller, Merck Research Laboratories, West Point, PA.
167. J. A. Gilbert and E. Richelson, Eur. J. Pharmacol., 99, 245 (1984). Neurotensin Stimulates Formation of Cyclic-GMP in Murine Neuro-Balstoma Clone N1E-115.
168. Y.-P. Pang, J. Zaidi, A. P. Kozikowski. B. Cusack, and E. Richelson, J. Comput. Aided Mol. Design, 8, 433 (1994). Rational Design of Novel Neurotensin Mimetics: Discovery of a Pharmacologically Unprecedented Agent Exhibiting Concentration-Dependent Dual Effects as Antagonist and Full Agonist.
169. D. C. Rees and J. C. Hunter, in Comprehensive Medicinal Chemistry. The Rational Design, Mechanistic Study & Therapeutic Application of Chemical Compounds, Membranes & Receptors, J. C. Emmett, Eds., Pergamon Press, New York, 1990, Vol. 3, pp. 805-846. Opioid Receptors.
170. T. Su, H. Nakanishi, L. Xue, B. Chen, S. Tuladhar, M. E. Johnson, and M. Kahn, Bioorg. Med. Chem. Lett., 3, 835 (1993). Nonpeptide β-Turn Mimetics of Enkephalin.
171. P. E. Smith, L. X. Dang, and B. M. Pettitt, J. Am. Chem. Soc., 113, 67 (1991). Simulation of the Structure and Dynamics of the Bis(penicillamine) Enkephalin Zwitterion.
172. B. Gardner, H. Nakanishi, and M. Kahn, Tetrahedron, 49, 3433 (1993). Conformationally Constrained Nonpeptide β-Turn Mimetics of Enkephalin.
173. B. L. Currie, J. L. Krstenansky, Z.-L. Lin, J. Ungwitayatorn, Y.-H. Lee, M. del Rosario-Chow, W.-S. Sheu, and M. E. Johnson, Tetrahedron, 49, 3489 (1993). Design and Synthesis of a Bicyclic Non-Peptide β-Bend Mimetic of Enkephalin.
174. 2 Receptor: Evidence for Modulation of Agonist Affinity States in Bovine Striatal Membranes.
175. 2.
176. D. M. Ferguson and D. J. Raber,J. Am. Chem. Soc., 111,4371 (1989). A New Approach to Probing Conformational Space with Molecular Mechanics: Random Incremental Pulse Search.
177. D. M. Ferguson, W. A. Glauser, and D. J. Raber, J. Comput. Chem., 10, 903 (1989). Molecular Mechanics Conformational Analysis of Cyclononane using the RIPS Method and Comparison with Quantum-Mechanical Calculations.
178. 2.
179. 5" Hydrogen-Bonded Conformation in the Peptidomimetic 2-Oxo-3(R)-[2(S)-(pyrrolidinylcarbony])amino]-1-pyrrolidineaceramide.
180. See, for example, M. Miyamoto, N. Yamazaki, A. Nagaoka, and Y. Nigawa, in Thyrotropin Releasing Hormone: Biomedical Significance, G. Metcalf, and I. M. D. Jackson, Eds., Annals of the New York Academy of Science, New York, pp. 508 ff., 1989.
181. K. Kamiya, M. Takamoto, Y. Wada, M. Fujino, and M. Nishikawa, J. Chem. Soc. Chem. Commun., 438 (1980). Molecular Conformation of Thyrotropin Releasing Hormone from the X-Ray Analysis of its Tartrate.
182. J. Vicar, E. Abillon, F. Toma, F. Piriou, K. Lintner, K. Blaha, P. Fromageot, and S. Fermandjian, FEBS Lett., 97, 275 (1979). Two Conformations of TRH in Solution.
183. M. L. Moore, Ph.D. Thesis, Washington University, St. Louis, MO, 1978, p. 23. Probing the Thyroliberin Receptor.
184. J. L. Font, Ph.D. Thesis, Washington University, St. Louis, MO, 1986. Computer-Assisted Drug Design and the Receptor-Bound Conformation of Thyrotropin Releasing Hormone (TRH): Design and Synthetic Approaches Towards Rigid TRH Analogs.
185. G. L. Oison, H.-C. Cheung, E. Chiang, V. S. Madison, J. Sepinwall, G. P. Vincent, A. Winokur, and K. A. Gary, J. Med. Chem., 38, 2866 (1995). Peptide Mimetics of Thyrotropin-Releasing Hormone Based on a Cyclohexane Framework: Design, Synthesis, and Cognition-Enhancing Properties.
186. A. S. Dutta, in Comprehensive Medicinal Chemistry. The Rational Design, Mechanistic Study & Therapeutic Application of Chemical Compounds, Vol. 3, Membranes & Receptors, Pergamon Press, New York, 1990, pp. 1001-1022. Tachykinin Receptors.
187. S. H. Buck, The Tachykinin Receptors, Humana Press, Totowa, NJ, 1994.
188. D. G. Payan, Annu. Rev. Med. Chem., 40, 341 (1989). Neuropeptides and Inflammation: The Role of Substance P.
189. M. Chorev, E. Roubini, C. Gilon, and Z. Selinger, Biopolymers, 31, 725 (1991). Toward Nonpeptidal Substance P Mimetic Analogues: Design, Synthesis, and Biological Activity.
190. See, for example, J. A. Lowe III, S. E. Drozda, R. M. Snider, D. P. Longo, S. H. Zorn, J. Morrone, E. R. Jackson, S. McLean, D. K. Bryce, J. Broder, A. Nagahisa, Y. Kanai, O. Suga, and M. Tsuchiya,J. Med. Chem., 35, 2591 (1992). The Discovery of (2S,3S)-cis-2-Diphenylmethyl-N-[(2-methoxyphenyl)methyl]-l-azabicyclo[2.2.2]- octan-3-amine as a Novel, Nonpeptide Substance P Antagonist.
191. R. Sarabu, K. Lovey, V. S. Madison, D. C. Fry, D. N. Greeley, C. M. Cook, and G. L. Olson, Tetrahedron, 49, 3629 (1993). Design, Synthesis and Three-Dimensional Structural Characterization of a Constrained Ω-Loop Excised from Interleukin 1α.
192. B. Graves, H. M. Hatada, W. A. Hendrickson, J. K. Miller, V. S. Madison, and Y. Satow, Biochemistry, 29, 2679 (1990). Structure of Interleukin 1α at 2.7 Å Resolution.
193. R. M. Burch, Ed., Bradykinin Antagonists. Basic and Clinical Research, Dekker, New York, 1991.
194. M. Sato, J. Y. H. Lee, H. Nakanishi, M. E. Johnson, R. A. Chrusciel, and M. Kahn, Biochem. Biophys. Res. Commun., 187, 999 (1992). Design, Synthesis and Conformational Analysis of γ-Turn Peptide Mimetics of Bradykinin.
195. I. L. Karle, J. Am. Chem. Soc., 100, 1286 (1978). Crystal Structure and Conformation of cyclo-(Glycylprolylglycyl-D-alanylprolyl) Containing 4 → 1 and 3 → 1 Intramolecular Hydrogen Bonds.
196. J. M. Salvino, P. R. Seoane, B. D. Douty, M. M. A. Awad, R. E. Dolle, W. T. Houck, D. M. Faunce, and D. G. Sawutz, J. Med. Chem., 36, 2583 (1993). Design of Potent Non-Peptide Competitive Antagonists of the Human Bradykinin B, Receptor.
197. 2 Receptor Antagonist.
198. J. M. Salvino, P. R. Seoane, and R. E. Dolle,J. Comput. Chem., 14, 438 (1993). Conformational Analysis of Bradykinin by Annealed Molecular Dynamics and Comparison to NMR Derived Conformations.
199. D. J. Kyle, J. A. Martin, R. M. Burch, J. P. Carter, S. Lu, S. Meeker, J. C. Prosser, J. P. Sullivan, J. Togo, L. Noronha-Blob, J. A. Sinsko, R. F. Walters, L. W. Whaley, and R. N. Hiner, J. Med. Chem., 34, 2649 (1991). Probing the Bradykinin Receptor: Mapping the Geometric Topography Using Ethers of Hydroxyproline in Novel Peptides.
200. D. J. Kyle, J. A. Martin, S. G. Farmer, and R. M. Burch, J. Med. Chein., 34, 1230 (1991). Design and Conformational Analysis of Several Highly Potent Bradykinin Receptor Antagonists.
201. D. J. Kyle, L. M. Green, P. R. Blake, D. Smithwick, and M. F. Summers, Peptide Res., 5, 206 (1992). A Novel β-Turn Mimic Useful for Mapping the Unknown Topology of Peptide Receptors.
202. H. U. Saragovi, D. Fitzpatrick, A. Raktabutr, H. Nakanishi, M. Kahn, and M. I. Greene, Science, 253, 792 (1991). Design and Synthesis of a Mimetic from an Antibody Complementarity-Determining Region.
203. W. R. Tulip, J. N. Varghese, W. G. Laver, R. G. Webster, and P. M. Colman, J. Mol. Biol., 227, 122 (1992). Refined Crystal Structure of the Influenza Virus N9 Neuraminidase-NC41 Fab Complex.
204. M. L. Smythe and M. von Itzstein, J. Am. Chein. Soc., 116, 2725 (1994). Design and Synthesis of a Biologically Active Antibody Mimic Based on an Antibody-Antigen Crystal Structure.
205. W. C. Ripka, G. V. De Lucca, A. C. Bach II, R. S. Pottorf, and J. M. Blaney, Tetrahedron, 49, 3609 (1993). Protein β-Turn Mimetics II: Design, Synthesis, and Evaluation in the Cyclic Peptide Gramicidin S.
206. T. K. Hayes, L. L. Keeley, and D. K. Knight, Biochem. Biophys. Res. Commun., 140, 674 (1986). Insect Hypertrehalosemic Hormone: Isolation and Primary Structure from Blaberus discoidalis Cockroaches.
207. M. Sato, M. Kahn, Z. Lin, M. E. Johnson, and T. K. Hayes, Bioorg. Med. Chem. Lett., 3, 1277 (1993). Design and Synthesis of Hypertrehalosemic Hormone Mimetics.
208. G. A. Petsko and D. Tsernoglou, FEBS Lett., 68, 1 (1976). The Crystal Structure of a Post-Synaptic Neurotoxin from Sea Snake at 2.2 A Resolution.
209. M. Kahn and S. Wilke, Peptide Chem., Struct. Biol., Proc. 11th Am. Peptide Symp., 489 (1990). The Design and Synthesis of Nonpeptide Mimetics of Erabutoxin B.
210. M. Kahn, B. Chen, and P. Zieske, Heterocycles, 25, 29 (1987). The Design and Synthesis of a Nonpeptide Mimic of Erabutoxin.
211. M. Kahn, H. Nakanishi, T. Su, J. Y.-H. Lee, and M. E. Johnson, Int. J. Peptide Protein Res., 38, 324 (1991). Design and Synthesis of Nonpeptide Mimetics of Jaspamide.
212. T. M. Zabriskie, J. A. Klocke, C. M. Ireland, A. H. Marcus, T. F. Molinski, D. J. Faulkner, C. Xu, and J. C. Clardy, J. Am. Chem. Soc., 108, 3123 (1986). Jaspamide, a Modified Peptide from a Jaspis Sponge, with Insecticidal and Antifungal Activity.
213. T. Yamazaki, Y.-F. Zhu, A. Probstl, R. K. Chadha, and M. Goodman, J. Org. Chem., 56, 6644 (1991). Probing a Molecular Model of Taste Utilizing Peptidomimetic Stereoisomers of 2-Aminocyclopentanecarboxylic Acid Methyl Ester.
214. T. Yamazaki, E. Benedetti, D. Kent, and M. Goodman, Angew. Chem. Int. Ed. Engl., 33, 1437 (1994). Conformational Requirements for Sweet-Tasting Peptides and Peptidomimetics.
215. M. Kahn, S. Wilke, B. Chen, K. Fujita, Y-H. Lee, and M. E. Johnson, J. Mol. Recog., 1, 75 (1988). The Design and Synthesis of Mimetics of Peptide β-Turns.
216. M. J. Genin and R. L. Johnson, J. Am. Chem. Soc., 114, 8778 (1992). Design, Synthesis and Conformational Analysis of a Novel Spiro-Bicyclic System as a Type II β-Turn Peptidomimetic.
217. G. L. Olson, M. E. Voss, D. E. Hill, M. Kahn, V. S. Madison, and C. M. Cook, J. Am. Chem. Soc., 112, 323 (1990). Design and Synthesis of a Protein β-Turn Mimetic.
218. T. P. Straatsma, in Reviews in Computational Chemistry, K. B. Lipkowitz and D. B. Boyd, Eds., VCH Publishers, New York, 1996, Vol. 9, pp. 81-127. Free Energy by Molecular Simulation.
219. See also, L. M. Balbes, S. W. Mascarella, and D. B. Boyd, in Reviews in Computational Chemistry, K. B. Lipkowitz and D. B. Boyd, Eds., VCH Publishers, New York, Vol. 5, pp. 357-379. A Perspective of Modern Methods in Computer-Aided Drug Design.